You just read:

Egalet Human Abuse Potential Data at American Pain Society Annual Meeting Demonstrates Significantly Lower Intranasal Abuse Potential of ARYMO™ ER Compared to MS Contin®

News provided by

Egalet

May 12, 2016, 08:00 ET